Press releases

Randomized study of nearly 3,000 patients to evaluate Company's third-generation drug-eluting stent technology

Next-generation balloon catheter technology catheter developed specifically to address physicians' needs in optimizing coronary stent deployment

Company's iLab® Ultrasound Imaging System compatible with leading X-ray systems

Presentations to include analyses from SYNTAX trial, as well as clinical data supporting the performance of drug-eluting stents

Company expands Sterling line of peripheral angioplasty balloon catheters to include long balloons designed for below-the-knee procedures

Next-generation system strengthens Company's endometrial ablation portfolio for the treatment of menorrhagia

ACUITY Break-Away™ Lead Delivery System designed to place leads in veins of varying sizes, including difficult-to-access veins

Approval includes specific indication for treatment of diabetic patients

Upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data

Presentations will provide new insights for physicians who treat patients with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds)

Results of study using Boston Scientific's WallFlex® Duodenal Stent presented at Digestive Disease Week®

EVIDENCE Trial to study Boston Scientific's Precision Plus™ Spinal Cord Stimulator System

Positive results to be presented for SpyGlass® Direct Visualization System, Radial Jaw® 4 Biopsy Forceps and WallFlex® Duodenal Stents

Educational forum includes lab training sessions and online community for urogynecologists, urologists and surgical gynecologists

Agreement relates to product advisories issued in 2005, before Boston Scientific acquired Guidant

Company records $1.8 billion goodwill impairment charge

Major advance in guidewire technology provides exceptional torque and flexibility for coronary procedures

A live webcast and replay of the January 11, 2011 conference will be available. Learn how to tune in.

A live webcast and replay of the May 4, 2011 conference will be available

Exclusive agreement promotes access to testing solutions for female urinary incontinence

Company is positioned to fully meet customer demand for COGNIS and TELIGEN within 24 hours

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2010...

Company's CRT-Ds recommended for asymptomatic and mild heart failure patients

Trials to evaluate small vessel and long lesion versions of platinum chromium PROMUS® Element™ Stent System

Boston Scientific applies to FDA for expanded indications for TAXUS Express and TAXUS® Liberte® Stents in AMI patients

Analysis of the data presented at the American College of Cardiology Annual Scientific Sessions

Manufacturing process changes were not submitted for FDA approval; no indication that changes pose any risk to patient safety

First and only premounted, balloon-expandable stent approved specifically for use in iliac arteries

Clinical data presentations to include 12-month results for third-generation TAXUS® Element™ drug-eluting stent

A webcast of the March 2 session will be available. Learn how to tune in live or watch the replay

Article reported a case summary of a patient who had been implanted subcutaneously with a Cognis cardiac resynchronization therapy defibrillator

New structure, leadership team and targeted portfolio changes will focus on sales excellence and cost effectiveness

"We delivered a quarter in line with expectations," said Ray Elliott, President and CEO

Settles three patent disputes with Johnson & Johnson (J&J) that date back to 2003

The patents relate to coatings (drug and polymer) for drug-eluting stents

Boston Scientific will webcast its February 11 conference call with financial results and business highlights for Q4 and FY 2009. Learn how to tune in.

Multi-center, prospective study plans to enroll 187 patients at 11 centers worldwide over the next 18 months

Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms

A webcast of the January 12 session will be available. Learn how to tune in live or watch the replay

MAPS clinical trial studying the coiling of intracranial aneurysms reaches its goal of 630 patients, enrolled at 47 hospitals in 11 countries

Company to contribute data to industry-sponsored Dual Antiplatelet Therapy (DAPT) Study

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement with the U.S. Department of Justice regarding...

Former Tyco executive "will bring an impressive range of global management experience to our Board," said Pete Nicholas, Chairman of the Board

Company to use the net proceeds for general corporate purposes, including prepaying its bank term loan due April 2011

Company expects the offering to close on December 14, 2009, subject to standard closing conditions

A webcast of the December 1 session will be available. Learn how to tune in live or watch the replay

Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets

Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention

Results from two clinical studies will be presented at the Global Congress for Minimally Invasive Gynecology (AAGL)

COGNIS® CRT-D and TELIGEN® ICD are the world's smallest and thinnest high-energy devices